6533b7dbfe1ef96bd126ffa4

RESEARCH PRODUCT

Physico-chemical stability of eribulin mesylate containing concentrate and ready-to-administer solutions.

Hans-peter LippJudith ThiesenIrene KrämerKirsten C Spindeldreier

subject

Eribulin MesylateChromatographybusiness.industryReproducibility of ResultsInjection solutionPharmacologyKetonesHigh-performance liquid chromatographyPharmaceutical SolutionsOncologyDrug StabilityMedicinePharmacology (medical)Chemical stabilitybusinessFuransChromatography High Pressure LiquidDrug Packaging

description

Objectives The aim of this study was to determine the stability of commercially available eribulin mesylate containing injection solution as well as diluted ready-to-administer solutions stored under refrigeration or at room temperature. Methods Stability was studied by a novel developed stability-indicating reversed-phase high-performance liquid chromatography (RP-HPLC) assay with ultraviolet detection (detection wavelength 200 nm). Triplicate test solutions of eribulin mesylate containing injection concentrate (0.5 mg/mL) and with 0.9% sodium chloride solution diluted ready-to-administer preparations (0.205 mg/mL eribulin mesylate in polypropylene (PP) syringes, 0.020 mg/mL eribulin mesylate in polypropylene/polyethylene (PE) bags) were stored protected from light either at room temperature (25℃) or under refrigeration (2–8℃). Samples were withdrawn on day 0 (initial), 1, 3, 5, 7, 14, 21 and 28 of storage and assayed. Physical stability was determined by measuring the pH value once a week and checking for visible precipitations or colour changes. Results The stability tests revealed that concentrations of eribulin mesylate remained unchanged over a period of 28 days irrespective of concentration, container material or storage temperature. Neither colour changes nor visible particles have been observed. The pH value varied slightly over time but remained in the stability favourable range of 5–9. Conclusion Eribulin mesylate injection (0.5 mg/mL) is physico-chemically stable over a period of 28 days after first puncture of the vial. After dilution with 0.9% NaCl vehicle solution, ready-to-administer eribulin mesylate injection solutions (0.205 mg/mL in PP syringe) and infusion solutions (0.02 mg/mL in prefilled PP/PE bags) are physico-chemically stable for a period of at least four weeks either refrigerated or stored at room temperature. For microbiological reasons storage under refrigeration is recommended.

10.1177/1078155213492449https://pubmed.ncbi.nlm.nih.gov/23812666